Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.5201
−$0.0001 · -0.02%
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
Previous close
$0.5201
−$0.0001 · -0.02%
Pre-market
$0.5201
$0.00 · 0.00%
Sep 9, 8:56 AM ET
Regular session · ET · Market data may be delayed.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
Day range
Current $0.5201
52-week range
Current $0.5201
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
34
Expensive
Sentiment
44
Mixed
Risk
59
Elevated Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
Day range
Current $0.5201
52-week range
Current $0.5201
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.23M USD | 3.5M USD | 2.9M USD | 2.93M USD | 2.4M USD |
| Cost of goods sold | 2.32M USD | 1.19M USD | 1.98M USD | 2.12M USD | 1.94M USD |
| Gross profit | −1.09M USD | 2.3M USD | 922.96K USD | 807.11K USD | 459.39K USD |
| Research and development | 2.15M USD | 2.04M USD | 3.3M USD | 4.5M USD | 8.39M USD |
| Selling, general, and administrative | 5.76M USD | 6.13M USD | 5.82M USD | 6.42M USD | 6.7M USD |
| Operating expenses | 6.06M USD | 8.2M USD | 9.15M USD | 10.97M USD | 15.19M USD |
| Interest income | 284.09K USD | 456.99K USD | 416.69K USD | 180.42K USD | 51.7K USD |
| Interest expense | 455.9K USD | 427.97K USD | — | — | — |
| Depreciation and amortization | — | — | 38.42K USD | — | 3.49M USD |
| Operating income | −7.15M USD | −5.9M USD | −8.23M USD | −10.17M USD | −14.73M USD |
| Net income | −7.36M USD | −5.81M USD | −6.8M USD | −9.74M USD | −13.07M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
476.81% upsidePrice history unavailable
High $3.00Average $3.00Low $3.00Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
